Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells

Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrà, Giovanna, Cartellà, Antonio, Maffeo, Beatrice, Morotti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842740/
https://www.ncbi.nlm.nih.gov/pubmed/31807112
http://dx.doi.org/10.2147/BLCTT.S228815
_version_ 1783468085451161600
author Carrà, Giovanna
Cartellà, Antonio
Maffeo, Beatrice
Morotti, Alessandro
author_facet Carrà, Giovanna
Cartellà, Antonio
Maffeo, Beatrice
Morotti, Alessandro
author_sort Carrà, Giovanna
collection PubMed
description Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs.
format Online
Article
Text
id pubmed-6842740
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68427402019-12-05 Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells Carrà, Giovanna Cartellà, Antonio Maffeo, Beatrice Morotti, Alessandro Blood Lymphat Cancer Review Chronic Myeloid Leukaemia is a myeloproliferative disorder driven by the t(9;22) chromosomal translocation coding for the chimeric protein BCR-ABL. CML treatment represents the paradigm of molecular therapy of cancer. Since the development of the tyrosine kinase inhibitor of the BCR-ABL kinase, the clinical approach to CML has dramatically changed, with a stunning improvement in the quality of life and response rates of patients. However, it remains clear that tyrosine kinase inhibitors (TKIs) are unable to target the most immature cellular component of CML, the CML stem cell. This review summarizes new insights into the mechanisms of resistance to TKIs. Dove 2019-11-06 /pmc/articles/PMC6842740/ /pubmed/31807112 http://dx.doi.org/10.2147/BLCTT.S228815 Text en © 2019 Carrà et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Carrà, Giovanna
Cartellà, Antonio
Maffeo, Beatrice
Morotti, Alessandro
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_full Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_fullStr Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_full_unstemmed Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_short Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
title_sort strategies for targeting chronic myeloid leukaemia stem cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842740/
https://www.ncbi.nlm.nih.gov/pubmed/31807112
http://dx.doi.org/10.2147/BLCTT.S228815
work_keys_str_mv AT carragiovanna strategiesfortargetingchronicmyeloidleukaemiastemcells
AT cartellaantonio strategiesfortargetingchronicmyeloidleukaemiastemcells
AT maffeobeatrice strategiesfortargetingchronicmyeloidleukaemiastemcells
AT morottialessandro strategiesfortargetingchronicmyeloidleukaemiastemcells

Ejemplares similares